Madrigal Pharmaceuticals
MDGL
156 hedge funds and large institutions have $1.85B invested in Madrigal Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 60 increasing their positions, 43 reducing their positions, and 29 closing their positions.
313% more call options, than puts
Call options by funds: $101M | Put options by funds: $24.5M
40% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 43
28% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 29
5% more funds holding
Funds holding: 148 → 156 (+8)
2.89% more ownership
Funds ownership: 53.27% → 56.15% (+2.9%)
19% less capital invested
Capital invested by funds: $2.27B → $1.85B (-$424M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$73.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.8M |
| 4 |
BlackRock
New York
|
+$21.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$21.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$55.8M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$26.6M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$25.8M |
| 4 |
PC
PointState Capital
New York
|
-$23.7M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$17.4M |
MDGL Hedge Fund Activity: Q3 2018 in Review
156 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2018, worth a combined $1.85B — down 19% from $2.27B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new MDGL positions and 29 closed out — a net gain of 8 holders — while 60 added to existing stakes and 43 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $73.8M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $55.8M sold.
- 156 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2018, up from 148 in Q2 2018.
- Funds reported $1.85B of Madrigal Pharmaceuticals stock for Q3 2018, down 19% quarter-over-quarter.
- 37 funds opened new Madrigal Pharmaceuticals positions in Q3 2018 and 29 closed out, a net change of +8 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2018 was Capital Research Global Investors, an estimated $73.8M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2018 was EcoR1 Capital, an estimated $55.8M sold.
Based on aggregated 13F filings for Q3 2018.